ArticleAnnals of medicine and surgery (2012)2022
Evaluation of serum levels of cathepsin S among colorectal cancer patients.
Article in Annals of medicine and surgery (2012), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Cathepsin S regulates antitumor immunity through autophagic degradation of PD-L1 in colorectal cancer cells.Cancer immunology, immunotherapy : CII · 2025Article
- Cathepsins: Emerging targets in the tumor ecosystem to overcome cancers.Seminars in cancer biology · 2025Review
- Assessment of the diagnostic value of serum cathepsin S and its correlation with HDL subclasses in patients with non-Hodgkin's lymphoma.Journal of medical biochemistry · 2024Article
- The causal relationship between cathepsins and digestive system tumors: a Mendelian randomization study.Frontiers in oncology · 2024Article
- Cathepsin S inhibitor reduces high-fat-induced adipogenesis, inflammatory infiltration, and hepatic lipid accumulation in obese mice.Annals of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Colorectal cancer is the third most common cancer worldwide. Cathepsins are protease that are known to be involved in cancer progression and metastasis. The aim of this study is to evaluate the levels of serum cathepsin S in patients and control subjects and its effects on the prognosis of the cancer. Methods: In this case-control study, colorectal cancer patients referred to our gastroenterology clinic were included. The control group consisted of healthy individuals. Cathepsin S levels were analyzed in these patients and the check list consisting of demographic data, cancer stage, colonoscopy findings, CEA marker and cathepsin S levels were recorded. Results: Of 80 patients and healthy controls included in the study, age, gender and BMI were not significantly different among the two groups, p = 0.265, p = 0.752 and p = 0.2, respectively. Cathepsin S levels were significantly greater in-patient group p < 0.001 and was significantly correlated with the stage of the tumor. CEA marker was also linear related with the increased levels of cathepsin S, p < 0.001. Conclusion: Our study concluded that cathepsin S is elevated in the cancer patients and can be a significant marker for the prognosis of colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.